{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:07:57Z","timestamp":1791464877110,"version":"4.3.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.neuropharm.2010.04.012","type":"journal-article","created":{"date-parts":[[2010,4,22]],"date-time":"2010-04-22T08:35:57Z","timestamp":1271925357000},"page":"112-120","source":"Crossref","is-referenced-by-count":29,"title":["Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801"],"prefix":"10.1016","volume":"59","author":[{"given":"Mar\u00eda Cecilia","family":"Scorza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Casta\u00f1\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anal\u00eda","family":"Bortolozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Artigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2010.04.012_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/cercor\/bhg128","article-title":"Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex","volume":"14","author":"Amarg\u00f3s-Bosch","year":"2004","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0022-3565(24)35047-5","article-title":"Characterization of MK-801-induced behaviour as a putative rat model of psychosis","volume":"290","author":"Andine","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"28","key":"10.1016\/j.neuropharm.2010.04.012_bib4","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1523\/JNEUROSCI.0563-04.2004","article-title":"Variability in the benzodiazepine response of serotonin 5-HT1A receptor null mice displaying anxiety-like phenotype: evidence for genetic modifiers in the 5-HT-mediated regulation of GABA(A) receptors","volume":"24","author":"Bailey","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2010.04.012_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1046\/j.1471-4159.2003.02267.x","article-title":"In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice","volume":"88","author":"Bortolozzi","year":"2004","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(97)01234-X","article-title":"Dopamine D4 receptor and anxiety: behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze","volume":"335","author":"Cao","year":"1997","journal-title":"Eur. J.\u00a0Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0166-2236(90)90108-M","article-title":"Interactions between glutamatergic and monoaminergic systems within the basal ganglia \u2013 implications for schizophrenia and Parkinson\u2019s disease","volume":"13","author":"Carlsson","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s007020050144","article-title":"The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist-than dopamine agonist-induced hyperactivity in mice","volume":"106","author":"Carlsson","year":"1999","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib13","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1007\/BF02245007","article-title":"Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates","volume":"112","author":"Casey","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-008-1205-9","article-title":"The absence of 5-HT1A receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex","volume":"200","author":"Casta\u00f1\u00e9","year":"2008","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2010.04.012_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00213-002-1256-2","article-title":"Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study","volume":"166","author":"Chou","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0022-3565(25)38157-7","article-title":"Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-d-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats","volume":"265","author":"Criswell","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-199710000-00001","article-title":"Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice","volume":"20","author":"Deustch","year":"1997","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib19","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action","volume":"25","author":"D\u00edaz-Mataix","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejphar.2007.01.010","article-title":"The effects of 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) on food intake in non-deprived C57BL6 mice","volume":"559","author":"Ebenezer","year":"2007","journal-title":"Eur. J.\u00a0Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","article-title":"Animal behaviour models of the mechanisms underlying antipsychotic atypicality","volume":"27","author":"Geyer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130050165","article-title":"Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice","volume":"129","author":"Gleason","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0014-2999(95)00624-9","article-title":"(R)8-OH-DPAT, a 5-HT1A agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens","volume":"287","author":"Ichikawa","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib26","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1073\/pnas.0308455101","article-title":"NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex","volume":"101","author":"Jackson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib29","doi-asserted-by":"crossref","first-page":"14843","DOI":"10.1073\/pnas.0704848104","article-title":"Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine","volume":"104","author":"Kargieman","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-003-1582-z","article-title":"NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development","volume":"169","author":"Krystal","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3565(24)38019-X","article-title":"Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens","volume":"288","author":"Kuroki","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0028-3908(03)00145-X","article-title":"The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade","volume":"45","author":"Leriche","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(93)90015-A","article-title":"Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats","volume":"242","author":"L\u00f6scher","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF01292622","article-title":"The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist","volume":"103","author":"Maj","year":"1996","journal-title":"J. Neural Transm."},{"issue":"1","key":"10.1016\/j.neuropharm.2010.04.012_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2010.04.012_bib40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2010.04.012_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0022-3565(24)38052-8","article-title":"S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4 fluorophenyl) ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol","volume":"288","author":"Millan","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib42","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib43","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1196\/annals.1300.065","article-title":"Glutamatergic animal models of schizophrenia","volume":"1003","author":"Moghaddam","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0092-8674(00)81972-8","article-title":"Mice with reduced NMDA receptor expression display behaviours related to schizophrenia","volume":"98","author":"Mohn","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib46","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s007020170008","article-title":"A behavioural pattern analysis of hypoglutamatergic mice-effect of four different antipsychotics agents","volume":"108","author":"Nilsson","year":"2001","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib47","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.pnpbp.2005.11.010","article-title":"Differential effects of classical neuroleptics and a newer generation antipsychotics on the MK-801 induced behavioural primitivization in mouse","volume":"30","author":"Nilsson","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib48","doi-asserted-by":"crossref","first-page":"10734","DOI":"10.1073\/pnas.95.18.10734","article-title":"Increased anxiety of mice lacking the serotonin1A receptor","volume":"95","author":"Parks","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1385-299X(01)00110-6","article-title":"An in vivo binding assay to determine central \u03b11-adrenoceptor occupancy using [3H] prazosin","volume":"8","author":"Patel","year":"2001","journal-title":"Brain Res. Protoc."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1523\/JNEUROSCI.12-02-00440.1992","article-title":"Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding","volume":"12","author":"Pompeiano","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib51","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/S0014-2999(97)81951-6","article-title":"Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation","volume":"338","author":"Rollema","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1566-2772(03)00021-5","article-title":"Atypical antipsychotic drug actions: unitary or multiple mechanisms for \u2018atypicality\u2019?","volume":"3","author":"Roth","year":"2003","journal-title":"Clin. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib53","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0006-8993(93)91535-Z","article-title":"Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography","volume":"631","author":"Schotte","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib55","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1017\/S1461145708008432","article-title":"Prefrontal cortex lesions cause only minor effects on the hyperlocomotion induced by MK-801 and its reversal by clozapine","volume":"11","author":"Scorza","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib56","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib57","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0091-3057(89)90044-0","article-title":"Acute and subchronic effects of methylenedioxymethamphetamine [(+\/\u2212) MDMA] on locomotion and serotonin syndrome behaviour in the rat","volume":"32","author":"Spanos","year":"1989","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib58","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1523\/JNEUROSCI.20-22-08515.2000","article-title":"Involvement of 5-HT1A receptors in classical fear conditioning in C57BL\/6J mice","volume":"20","author":"Stiedl","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1566-2772(03)00017-3","article-title":"Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action","volume":"3","author":"Svensson","year":"2003","journal-title":"Clin. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0924-977X(01)00076-1","article-title":"Effects of selective 5-HT1A receptor antagonists on regional serotonin synthesis in the rat brain: an autoradiographic study with alpha-[14C]methyl-l-tryptophan","volume":"11","author":"Tohyama","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2010.04.012_bib61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(03)01280-9","article-title":"5-HT1A receptor knockout mouse as a genetic model of anxiety","volume":"463","author":"Toth","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10571-004-6918-7","article-title":"Effects of NMDA-receptor antagonist treatment on c-fos expression in rat brain areas implicated in schizophrenia","volume":"24","author":"V\u00e4is\u00e4nen","year":"2004","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib63","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0149-7634(95)00057-7","article-title":"Serotonergic mechanism in neuroleptic-induced catalepsy in the rat","volume":"20","author":"Wadenberg","year":"1996","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2010.04.012_bib64","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0893-133X(00)00150-0","article-title":"WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801","volume":"23","author":"Wedzony","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.04.012_bib65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00213-004-1944-1","article-title":"Bimodal effects of MK-801 on locomotion and stereotypy in C57BL\/6 mice","volume":"177","author":"Wu","year":"2005","journal-title":"Psychopharmacology"},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2010.04.012_bib66","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuropharm.2009.07.011","article-title":"Bidirectional modulation of classical fear conditioning in mice by 5-HT(1A) receptor ligands with contrasting intrinsic activities","volume":"57","author":"Youn","year":"2009","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390810001140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390810001140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:29:22Z","timestamp":1740022162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390810001140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":65,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0028390810001140"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2010.04.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}